Status:
COMPLETED
Basal Cell Carcinoma Recurrence After Mohs Surgery
Lead Sponsor:
Northwestern University
Conditions:
Basal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects. Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for remov...
Detailed Description
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in the United States, affecting nearly one million of all Americans. While BCC is rarely mortal, it has significant associated phy...
Eligibility Criteria
Inclusion
- Subjects with BCC lesions on the head, neck, genitalia, hands, or feet
- Subjects who have undergone Mohs micrographic surgery for BCC on or before December 31, 2006
- Subjects with a medical record at the respective site
- Subjects in a stable health condition, as determined by the principle investigator
Exclusion
- Subjects with basal cell nevus syndrome
- Subjects with lesions only in areas other than the head, neck, genitalia,
- hands and feet
- Subjects who have not followed up through the Department of Dermatology
- Subjects with recurrent BCC lesions diagnosed on or prior to the recorded date of Mohs surgery
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT00882791
Start Date
May 1 2008
End Date
May 1 2009
Last Update
December 2 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University Feinberg School of Medicine, Department of Dermatology
Chicago, Illinois, United States, 60611
2
DuPage Medical Group Dermatology
Naperville, Illinois, United States, 60563